« Return to News | Drug Sponsors

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

Garnier is scheduled to become vice chairman and will set to replace Robert Cawthorn. The other nominee is Robert Bertolini, former chief financial officer at Schering-Plough, who previously worked for 20 years with PriceWaterhouseCoopers. He acted as a senior advisor to companies such as Merck & Co and Johnson & Johnson.

Garnier said that "I’m very impressed with the company’s track record and where it stands today as Europe's largest biopharmaceutical company." He added that "Actelion's track record in translating superior drug discovery into meaningful therapeutic solutions is very exciting" and "I look forward to contributing to guiding the company through the next phase of growth."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.